Clinical Trial Update: Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma [Phase 1]

View source ↗

Summary

Phase I study evaluating intralesional BCG followed by ipilimumab in advanced metastatic melanoma was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Bacillus Calmette-Guerin (BCG) (Bacillus Calmette-Guerin)
• ipilimumab (ipilimumab)

Snippet

Sponsor: Ludwig Institute for Cancer Research | Conditions: Metastatic Melanoma | Phase 1 | Status: TERMINATED | Results posted: 2019-03-28